Gelonghui, March 25: An investor asked Changchun Hi-Tech (000661.SZ) on the investor interactive platform, “Can we talk about whether Gaoxin will enter the field of ophthalmology in the future?” The company replied that currently the company's EG017 ointment is used for patients with indications such as dry eye and phase II clinical trials.
长春高新(000661.SZ)：目前公司EG017软膏用于干眼症等适应症II期临床相关患者持续入组中
Changchun Hi-Tech (000661.SZ): Currently, the company's EG017 ointment is used for patients with dry eye and other indications in phase II clinical trials and continues to enroll
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.